Health-Related Quality of Life after Direct Acting Antiviral Treatment for Chronic Hepatitis C in a community Led Program | ||||
| Medical Journal of Viral Hepatitis | ||||
| Article 2, Volume 7.2, Issue 2, April 2023, Page 9-14 PDF (223.09 K) | ||||
| Document Type: Original article | ||||
| DOI: 10.21608/mjvh.2023.308934 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Gamal Shiha  1; AM Metwally2; R Soliman3; NNH Mikhail4
| ||||
| 1Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt Hepatology and Gastroenterology unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt | ||||
| 2Department of Community Medicine Research, Medical Division, National Research Center, Giza, Egypt | ||||
| 3Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt Tropical Medicine department, Faculty of Medicine, Port Said University, Port Said, Egypt | ||||
| 4Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt Department of Biostatistics and Cancer Epidemiology, South Egypt Cancer Institute, Assiut University, Egypt | ||||
| Abstract | ||||
| Background: Introduction: HCV infection causes significant impairment of health-related quality of life (HRQoL) and other patient-reported outcomes. Interferon-based treatment was strongly associated with a decreased HRQoL. Clinical trials showed that an interferon-free treatment also leads to a mild impairment of HRQoL during treatment that improves after end of treatment. Our aim was to assess the impact of Direct Acting Antiviral (DAA) treatment on HRQoL in a prospectively followed real-life cohort in the context of community-led program. Methods: HRQoL was assessed in 601 HCV-infected patients using the Short-Form 36 before the start of DAA treatment and was repeated after about 12 weeks of end of treatment when SVR was assessed. The patients were classified into two groups according to treatment regimen: Group I patients received 400 mg of sofosbuvir daily with weight-based ribavirin for 24 weeks, while Group II patients received daily oral sofosbuvir 400 mg and daclatasvir 60 mg for 12 weeks. Results: HRQoL domains (with the exception of role physical domain) showed improvement, regardless whether ribavirin was part of the treatment regimen or not. Both the physical and the mental component summary score increased significantly in each group, with no significant difference between the two treatment arms. Conclusion: The current real-world study confirms results from clinical trials that the majority of patients report an increased HRQoL after finishing HCV treatment. | ||||
| Keywords | ||||
| Chronic hepatitis C; DAA Treatment; Health Related Quality of Life | ||||
|
Statistics Article View: 174 PDF Download: 192 |
||||
